ADC Insights: From Technical Core to a Multi-Billion Dollar Market Overview

After a week of in-depth exploration, we have collectively completed a comprehensive understanding of ADC from its technical foundation to commercial practice. In this weekend special, let us systematically review this revolutionary breakthrough in precision medicine from a panoramic perspective.

01

—

📊 This week’s core content deep review

1. Technical Breakthrough: Evolution of ADC Technical Architecture

1.1 Core Structure Evolution Path

1.2 Three Major Technical Breakthrough Dimensions

🎯 Technical Insights: The collaborative evolution of three major technical dimensions drives ADC’s leap from “broad-spectrum damage” to “precise intelligent control,” systematically enhancing the treatment index.

Detailed Analysis of Key Technical Breakthroughs

2. Clinical Advancement: Reconstruction of Treatment Patterns

2.1 Core Drug Clinical Breakthrough Milestones

🧪 ADC Drug Core Clinical Data Comparison Table

2.2 Changes in Cancer Treatment Patterns

3. Commercial Breakthrough: Evolution of Market Patterns

3.1 Market Size Evolution Trajectory and Driving Forces

3.2 Global R&D Pipeline Distribution Characteristics

3.3 China’s Market Performance and Characteristics

3.4 Target Competition Landscape

02

—

🔬 Knowledge Advancement: In-Depth Comparison of ADC vs Targeted Drugs

ADC and Targeted Drug Clinical Application Decision Guide

🎯 Decision Insights: This pathway map reveals the profound shift in treatment logic from “etiology-driven” to “scenario-driven,” allowing patients without clear driving genes to receive precise treatment opportunities through ADC.

Multidimensional Comparative Analysis of Mechanisms of Action of ADC and Targeted Drugs

Table: Comprehensive Comparison of Mechanisms of Action

Clinical Selection of ADC and Targeted Drugs

Economic Comparison of ADC and Targeted Drugs

🎯 Summary and Clinical Insights:

• ADC is a powerful tool for overcoming drug resistance, addressing heterogeneity, and achieving significant tumor shrinkage especially valuable in later-stage treatments.

• Targeted drugs remain an unshakeable cornerstone in first-line treatment for patients with positive driving genes, chronic disease management, and targeting rare mutations.

03

—

💡 Investment Insights: New Framework for Value Assessment

Technical Platform Valuation System

Risk-Return Matrix and Investment Strategy

Investment Insights: The matrix shows that while the “breakthrough field” carries high risks, it represents the future direction of ADC technology; the intense competition in the “star field” suggests that investors need more precise target selection capabilities.

🎤 Selected Q&A from Readers

Q: How to manage interstitial lung disease (ILD) that occurs during ADC drug treatment?A: ILD is a key adverse event for some ADC drugs, and the management recommendations are as follows:

1. Grade 1 (asymptomatic): Temporarily stop the drug, closely monitor symptoms and imaging changes

2. Grade 2 (symptomatic): Immediately suspend medication and provide glucocorticoid treatment

3. Grades 3-4 (severe): Permanently stop medication, administer high-dose steroid pulse therapy, and consult a respiratory specialistPrevention Points: Assess risk factors before medication, and conduct regular imaging monitoring during treatment

Q: How to manage common adverse reactions of ADC drugs?A: Management strategies include:

• Bone marrow suppression: Regular monitoring of blood counts, G-CSF support, and dose adjustment if necessary

• Gastrointestinal reactions: Preventive antiemetics, timely rehydration, and nutritional support

• Liver and kidney function abnormalities: Monitor before and after treatment, adjust doses or suspend medication based on severity

• Skin reactions: Moisturizing care, symptomatic treatment, and dermatology consultation for severe cases

Q: What are the specific considerations for evaluating the efficacy of ADC drug treatment?A: Efficacy evaluation of ADC requires attention to:

1. Possible pseudoprogression: Tumor transient enlargement may occur early in treatment; comprehensive judgment should be made based on clinical symptoms

2. Delayed efficacy phenomenon: Some patients may have a delayed response; avoid premature determination of ineffectiveness

3. Timing of continuous medication: Even with partial remission, it is recommended to continue treatment until maximum efficacy is achieved

4. Dynamic monitoring of biomarkers: Monitoring of target expression changes can be conducted during treatment

🔭 Next Week’s Preview

“Pharmaceutical Daily”ADC 2.0 Era: Industry Depth and Future EcologyIntelligent Delivery Reshaping the Boundaries of Precision Treatment

I am Amy, focusing on the forefront of medicine and delivering deep insights

Copyright Notice:

This column’s content is based on publicly available information and professional analysis, with data up to the second quarter of 2025. The market data cited in this article comes from the 2025 negotiation materials from the Medical Insurance Bureau, various company financial reports, and IQVIA industry analysis reports. Feel free to share this content with proper attribution.

I know you are “reading“, remember to clickhere↓↓↓↓

Previous Issues:

Antibody-Drug Conjugates (ADC):

【Pharmaceutical Daily】001 | ADC Overview: The Technical Landscape of “Biological Missiles”

【Pharmaceutical Daily】002 | DS-8201: The Birth and Insights of a “Super ADC”

【Pharmaceutical Daily】003 | ADC Payloads: The Evolution from Chemotherapy Drugs to Top 1 Inhibitors

【Pharmaceutical Daily】004 | ADC Competitive Logic and Deep Layout

【Pharmaceutical Daily】005 | ADC Medical Insurance Negotiation – Pricing Strategies and Multi-Billion Dollar Market Forecast